Supernus logo
Supernus
SUPN | NASDAQ
Chart Builder DCF Calculator
$28.83
-$0.89 (-2.99%)
At close: Nov 16, 2026, 4:00 PM ET
$28.83
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Supernus Company Profile

Company profile explained

Company Profile

Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its portfolio of 11 marketed products spans opioid use disorder, psychiatry, and neurology, and includes SUBLOCADE, a long-acting injectable buprenorphine for opioid use disorder, along with sublingual OUD treatments; Qelbree, a non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD); GOCOVRI for dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy; ONAPGO for motor fluctuations in advanced Parkinson’s disease; ZURZUVAE for postpartum depression; and treatments for epilepsy, migraine, cervical dystonia, and chronic sialorrhea, including Oxtellar XR, Trokendi XR, APOKYN, and MYOBLOC. The company also advances a pipeline of novel CNS product candidates. Its products are sold primarily in the United States, with additional markets including Canada, Australia, France, and Germany. The company was formed through the November 2026 merger of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and is headquartered in Rockville, Maryland.

Key Executives

Name Position
Jack A. Khattar President, CEO & Director
Joseph J. Ciaffoni Chief Executive Officer & Director
Jeffrey W. Burris Chief Legal Officer
Ryan Preblick Chief Financial Officer
Alice G. Givens Company Secretary
Angela Colon-Mahoney Chief Human Resources Officer
Ann Wheeler Chief Medical Officer
Christian Heidbreder Chief Scientific Officer
Jason Thompson Vice President of Investor Relations
Ken Morici Senior Vice President of Manufacturing & Supply
Kevin L. Espinoza Chief Integrity & Compliance Officer
Patrick A. Barry Chief Commercial Officer
Timothy C. Dec Senior VP & CFO
Vanessa Procter Executive Vice President of Corporate Affairs

Latest SEC Filings

Date Type Title
Nov 04, 2026 4 Filing
Nov 04, 2026 4 Filing
Nov 04, 2026 4 Filing
Nov 04, 2026 4 Filing
Nov 04, 2026 4 Filing
Nov 04, 2026 4 Filing
Nov 04, 2026 4 Filing
Nov 04, 2026 4 Filing
Nov 04, 2026 4 Filing
Nov 04, 2026 3 Filing
View All SEC Filings ➞
Supernus
Supernus logo
Country United States
IPO Date Apr 30, 2012
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 827
CEO Jack A. Khattar

Contact Details

9715 Key West Avenue Rockville, Maryland 20850 United States

Stock Details

Ticker Symbol SUPN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001625297
CUSIP Number 45579U109
ISIN Number US45579U1097
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.